Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
Clinical trial NCT05008224 · COMPLETED
Trial details
- NCT number
- NCT05008224
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-07
- Primary completion
- 2023-10-11
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.